In a nutshell, LAG-3 has emerged as a viable option for cancer immunotherapy, but more study of these strategies is critical, particularly in the older population, where LAG-3 expression is significantly higher than in younger people (28, 58, 139). This evidence concerns the gene LAG3 and cancer.